CytomX Therapeutics, Inc. (CTMX) Insider William Michael Kavanaugh Sells 48,368 Shares
CytomX Therapeutics, Inc. (NASDAQ:CTMX) insider William Michael Kavanaugh sold 48,368 shares of the business’s stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $24.34, for a total transaction of $1,177,277.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) traded down 2.54% during midday trading on Friday, hitting $21.50. 215,136 shares of the stock were exchanged. CytomX Therapeutics, Inc. has a 12-month low of $9.85 and a 12-month high of $24.67. The company’s market cap is $792.64 million. The firm has a 50-day moving average price of $17.15 and a 200-day moving average price of $15.67.
CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.30). CytomX Therapeutics had a negative return on equity of 84.61% and a negative net margin of 206.33%. The business had revenue of $8.75 million during the quarter, compared to the consensus estimate of $4.95 million. On average, equities analysts predict that CytomX Therapeutics, Inc. will post ($1.47) EPS for the current year.
CTMX has been the subject of a number of research reports. Cowen and Company reissued a “buy” rating on shares of CytomX Therapeutics in a research report on Tuesday, August 8th. BidaskClub raised shares of CytomX Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, July 8th. Nomura boosted their price target on shares of CytomX Therapeutics to $44.00 and gave the company a “buy” rating in a research report on Wednesday. Bank of America Corporation reissued a “buy” rating and issued a $30.00 price target (up from $28.00) on shares of CytomX Therapeutics in a research report on Wednesday, August 9th. Finally, ValuEngine cut shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, September 15th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $32.67.
Several institutional investors have recently bought and sold shares of the company. EcoR1 Capital LLC bought a new stake in CytomX Therapeutics in the 1st quarter valued at about $13,729,000. Numeric Investors LLC bought a new stake in CytomX Therapeutics in the 2nd quarter valued at about $9,730,000. Perceptive Advisors LLC lifted its position in CytomX Therapeutics by 65.7% in the 1st quarter. Perceptive Advisors LLC now owns 1,530,659 shares of the biotechnology company’s stock valued at $26,434,000 after purchasing an additional 606,896 shares during the last quarter. Driehaus Capital Management LLC bought a new stake in CytomX Therapeutics in the 1st quarter valued at about $5,089,000. Finally, State Street Corp lifted its position in CytomX Therapeutics by 58.8% in the 2nd quarter. State Street Corp now owns 446,315 shares of the biotechnology company’s stock valued at $6,914,000 after purchasing an additional 165,342 shares during the last quarter. Institutional investors own 59.97% of the company’s stock.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.